Introducing Rely+On™ Virkon™ broad spectrum disinfectant, the new name for Rely+On™ MDC in the U.S. human health market sector
- Effective disinfection for institutional, food processing and public service facilities
- Proven effective against Norovirus, Influenza A virus, Salmonella enterica and Campylobacter jejuni
- Efficacious against prevalent hospital pathogens such as Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus faecalis and Respiratory Syncytial Virus
- Approved on U.S. EPA List N
USA, US –
Pittsburgh, Pa. –May 21, 2020– The premier human health disinfectant, Rely+On™ Multipurpose Disinfectant Cleaner (MDC), from specialty chemicals company LANXESS will be undergoing a name change in June, 2020.
As of June, LANXESS will transition Rely+On™ MDC to its new name, Rely+On™ Virkon™, in the U.S. The name change is in recognition of the Rely+On™ brand’s connection to the world-renowned portfolio of Virkon™ disinfectants and biocides.
The independently proven effective, flexible and convenient broad spectrum disinfectant formulation remains unchanged.
Rely+On™ Virkon™ can be used for the cleaning and disinfection of hard non-porous surfaces in institutional, commercial and public service facilities, including hospitals and nursing homes, Emergency Medical Services (EMS) facilities, laboratories, schools, food processing plants and many more.
The scientifically engineered formulation of Rely+On™ Virkon™ has a comprehensive data set against prevalent disease-causing pathogens that can affect human health. These include, but are not limited to, Norovirus, Influenza A virus, Salmonella enterica, Campylobacter jejuni and Methicillin-Resistant Staphylococcus Aureus (MRSA).
In regards to the current health crisis, LANXESS is actively increasing support for customers seeking disinfection products like Rely+On™ Virkon™. COVID-19 is caused by SARS-CoV-2. Rely+On™ Virkon™ kills similar viruses and therefore can be used against SARS-CoV-2 when used in accordance with the directions for use against Hepatitis A Virus and Norovirus on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/index.html for additional information.
The powder disinfectant concentrate is easy to prepare and use. Readily soluble in tap water, Rely+On™ Virkon™ dissolves into a solution which remains stable for up to 7 days, as a 1:100 solution*.
It can be easily applied using a mop, sponge, brush or spray device until surfaces are visibly clean*.
Material protection solutions from LANXESS
The products of the Material Protection Products business unit are used worldwide in many different applications. With its broad portfolio of antimicrobial active ingredients, preservatives and disinfectants, the business unit offers tailored solutions for customers in many industrial sectors. In addition to disinfection, these include the wood protection industry, the paint and coatings industry as well as the construction sector and the beverage industry. Material Protection Products also offers extensive technical service, regulatory support and project-specific research and development.
The LANXESS Material Protection Products business unit currently has a workforce of around 640 with production sites in the United States, Germany, China, India, Singapore, the UK and Brazil.
Customers seeking more information can reach out to the LANXESS business team at email@example.com.
* Please consult the Rely+On™ Virkon™ product container label for a comprehensive list of organisms and directions for use.
LANXESS is a leading specialty chemicals company with sales of EUR 6.8 billion in 2019. The company currently has about 14,300 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person’s officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.